江苏吴中(600200) - 2020 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was RMB -45,964,293.74, a decrease of 183.11% year-on-year[17] - Operating revenue for the first nine months was RMB 1,480,902,752.55, down 2.43% from the same period last year[17] - Basic and diluted earnings per share were both RMB -0.065, a decrease of 184.42% year-on-year[17] - The company anticipates a significant negative impact on profits due to the exit compensation agreement related to the suspended operations of its subsidiary, which may lead to a cumulative net loss for the year[30] - Investment income dropped by 86.54% to ¥1,955.25 million from ¥14,528.59 million, primarily due to the absence of gains from share buybacks and real estate equity transfers recognized in the previous year[29] - The company reported a total profit of -¥25,571,529.47 for Q3 2020, compared to -¥2,022,430.98 in Q3 2019[57] - The company's net profit for Q3 2020 was -¥14,600,466.78, compared to -¥14,760,220.95 in Q3 2019, indicating a slight improvement in losses[66] Cash Flow - The net cash flow from operating activities was RMB -99,303,646.06, a decline of 235.71% compared to the previous year[17] - Cash flow from operating activities in the first three quarters of 2020 was ¥3,283,304,491.32, an increase from ¥2,782,675,767.83 in the same period of 2019[72] - The company incurred a net cash outflow from operating activities of -¥99,303,646.06 in Q3 2020, contrasting with a net inflow of ¥73,175,030.81 in Q3 2019[72] - The net cash flow from financing activities was -102,269,764.69 RMB, a decline from a positive cash flow of 68,950,333.45 RMB in the same quarter last year[77] Assets and Liabilities - Total assets at the end of the reporting period reached RMB 4,264,463,020.38, an increase of 8.79% compared to the end of the previous year[17] - Current liabilities rose to ¥1,725,208,449.32, compared to ¥1,412,501,779.78, indicating an increase of about 22.1%[44] - The company's total liabilities reached ¥1,948,034,290.15, compared to ¥1,556,605,324.37, which is an increase of about 25.1%[44] - Long-term borrowings increased by 75.67% to ¥20,216.56 million from ¥11,508.29 million, indicating a rise in financing for pharmaceutical operations[27] - Short-term borrowings increased significantly to ¥1,218,928,707.81 from ¥878,272,816.90, reflecting a rise of approximately 38.8%[44] Shareholder Information - The total number of shareholders at the end of the reporting period was 88,337[20] - The largest shareholder, Suzhou Wuzhong Investment Holding Co., Ltd., held 17.24% of the shares[20] Government Support and Income - Government subsidies recognized in the current period amounted to RMB 5,154,798.93, totaling RMB 15,158,254.64 for the year-to-date[19] - Other income surged by 131.35% to ¥831.86 million from ¥359.57 million, mainly due to increased government subsidies received[29] Research and Development - Research and development expenses increased by 30.30% to ¥1,397.53 million from ¥1,072.57 million, reflecting higher investment in pharmaceutical R&D[29] - Research and development expenses increased to ¥3,162,721.03 in Q3 2020, up 101.3% from ¥1,572,679.77 in Q3 2019[53] Other Financial Metrics - The weighted average return on equity decreased by 4.27 percentage points to -1.97%[17] - Non-operating income and expenses resulted in a net loss of RMB -1,138,227.25 for the current period[19] - The total operating profit for the first three quarters of 2020 was -¥40,892,290.84, a significant decline from ¥108,610,286.06 in the same period of 2019[66]